Par Income Tax Expense vs Ebitda Analysis

PAR Stock   99.41  2.73  2.67%   
Par Drugs financial indicator trend analysis is much more than just breaking down Par Drugs And prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Par Drugs And is a good investment. Please check the relationship between Par Drugs Income Tax Expense and its Ebitda accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Income Tax Expense vs Ebitda

Income Tax Expense vs Ebitda Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Par Drugs And Income Tax Expense account and Ebitda. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Par Drugs' Income Tax Expense and Ebitda is 0.9. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Ebitda in the same time period over historical financial statements of Par Drugs And, assuming nothing else is changed. The correlation between historical values of Par Drugs' Income Tax Expense and Ebitda is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Par Drugs And are associated (or correlated) with its Ebitda. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Ebitda has no effect on the direction of Income Tax Expense i.e., Par Drugs' Income Tax Expense and Ebitda go up and down completely randomly.

Correlation Coefficient

0.9
Relationship DirectionPositive 
Relationship StrengthVery Strong

Income Tax Expense

Ebitda

Most indicators from Par Drugs' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Par Drugs And current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Par Drugs And. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
As of May 2, 2025, Selling General Administrative is expected to decline to about 11.4 M. In addition to that, Tax Provision is expected to decline to about 29.1 M
 2022 2023 2024 2025 (projected)
Total Revenue951.0M956.4M1.1B669.2M
Depreciation And Amortization32.3M34.4M39.5M33.2M

Par Drugs fundamental ratios Correlations

-0.650.57-0.60.87-0.31-0.860.880.160.89-0.33-0.70.420.890.710.55-0.78-0.290.740.51-0.740.89-0.730.92-0.340.81
-0.65-0.610.94-0.770.760.88-0.7-0.18-0.680.770.33-0.01-0.68-0.79-0.620.940.75-0.47-0.950.98-0.720.97-0.81-0.1-0.88
0.57-0.61-0.480.6-0.42-0.650.560.610.5-0.43-0.380.380.50.930.38-0.71-0.090.130.45-0.640.6-0.680.77-0.290.59
-0.60.94-0.48-0.780.770.85-0.73-0.01-0.690.780.40.14-0.69-0.66-0.690.90.78-0.59-0.910.96-0.710.94-0.740.02-0.89
0.87-0.770.6-0.78-0.65-0.970.990.220.98-0.67-0.710.230.980.750.62-0.93-0.520.850.67-0.860.99-0.880.88-0.320.91
-0.310.76-0.420.77-0.650.68-0.58-0.31-0.581.00.220.11-0.58-0.59-0.430.760.79-0.44-0.780.74-0.620.78-0.48-0.18-0.73
-0.860.88-0.650.85-0.970.68-0.94-0.24-0.940.70.61-0.21-0.94-0.82-0.630.980.59-0.75-0.790.94-0.960.95-0.920.19-0.92
0.88-0.70.56-0.730.99-0.58-0.940.190.99-0.6-0.720.220.990.710.63-0.88-0.450.890.6-0.810.99-0.830.85-0.40.87
0.16-0.180.61-0.010.22-0.31-0.240.190.16-0.30.030.240.160.630.17-0.290.02-0.120.14-0.170.26-0.280.36-0.250.17
0.89-0.680.5-0.690.98-0.58-0.940.990.16-0.6-0.740.31.00.660.53-0.86-0.480.90.59-0.780.99-0.80.82-0.290.86
-0.330.77-0.430.78-0.671.00.7-0.6-0.3-0.60.240.1-0.6-0.6-0.440.770.78-0.45-0.780.75-0.630.79-0.49-0.17-0.74
-0.70.33-0.380.4-0.710.220.61-0.720.03-0.740.24-0.66-0.74-0.38-0.080.530.02-0.73-0.10.46-0.710.45-0.610.38-0.67
0.42-0.010.380.140.230.11-0.210.220.240.30.1-0.660.30.27-0.47-0.130.340.13-0.23-0.040.3-0.050.32-0.020.22
0.89-0.680.5-0.690.98-0.58-0.940.990.161.0-0.6-0.740.30.660.53-0.86-0.480.90.59-0.780.99-0.80.82-0.290.86
0.71-0.790.93-0.660.75-0.59-0.820.710.630.66-0.6-0.380.270.660.59-0.86-0.340.320.67-0.810.75-0.850.9-0.280.75
0.55-0.620.38-0.690.62-0.43-0.630.630.170.53-0.44-0.08-0.470.530.59-0.67-0.470.490.67-0.70.57-0.690.66-0.480.59
-0.780.94-0.710.9-0.930.760.98-0.88-0.29-0.860.770.53-0.13-0.86-0.86-0.670.61-0.65-0.840.98-0.890.99-0.910.17-0.93
-0.290.75-0.090.78-0.520.790.59-0.450.02-0.480.780.020.34-0.48-0.34-0.470.61-0.44-0.890.68-0.470.7-0.35-0.4-0.62
0.74-0.470.13-0.590.85-0.44-0.750.89-0.120.9-0.45-0.730.130.90.320.49-0.65-0.440.42-0.60.85-0.60.6-0.360.72
0.51-0.950.45-0.910.67-0.78-0.790.60.140.59-0.78-0.1-0.230.590.670.67-0.84-0.890.42-0.90.62-0.90.660.20.77
-0.740.98-0.640.96-0.860.740.94-0.81-0.17-0.780.750.46-0.04-0.78-0.81-0.70.980.68-0.6-0.9-0.810.99-0.880.09-0.93
0.89-0.720.6-0.710.99-0.62-0.960.990.260.99-0.63-0.710.30.990.750.57-0.89-0.470.850.62-0.81-0.840.87-0.320.88
-0.730.97-0.680.94-0.880.780.95-0.83-0.28-0.80.790.45-0.05-0.8-0.85-0.690.990.7-0.6-0.90.99-0.84-0.880.11-0.92
0.92-0.810.77-0.740.88-0.48-0.920.850.360.82-0.49-0.610.320.820.90.66-0.91-0.350.60.66-0.880.87-0.88-0.370.87
-0.34-0.1-0.290.02-0.32-0.180.19-0.4-0.25-0.29-0.170.38-0.02-0.29-0.28-0.480.17-0.4-0.360.20.09-0.320.11-0.37-0.14
0.81-0.880.59-0.890.91-0.73-0.920.870.170.86-0.74-0.670.220.860.750.59-0.93-0.620.720.77-0.930.88-0.920.87-0.14
Click cells to compare fundamentals

Par Drugs Account Relationship Matchups

Par Drugs fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets763.8M786.9M888.7M1.0B1.2B763.9M
Other Current Liab19.7M42.0M59.0M21.1M24.2M24.9M
Total Current Liabilities159.8M148.6M139.9M124.4M112.0M123.4M
Total Stockholder Equity522.1M598.8M712.4M856.3M984.8M1.0B
Property Plant And Equipment Net343.7M343.5M386.9M413.3M372.0M305.2M
Net Debt(128.4M)(162.1M)(222.4M)(366.5M)(329.9M)(313.4M)
Retained Earnings291.3M368.0M481.6M625.5M719.3M755.3M
Accounts Payable67.2M106.6M80.9M53.6M61.6M75.1M
Cash211.6M162.1M222.4M366.5M421.5M442.6M
Non Current Assets Total352.0M351.3M394.3M419.9M377.9M311.6M
Non Currrent Assets Other8.2M7.6M7.3M6.4M5.8M6.3M
Other Assets7.1M7.6M7.6M7.3M8.4M5.1M
Cash And Short Term Investments211.6M162.1M222.4M366.5M421.5M442.6M
Net Receivables126.2M217.4M218.2M137.1M157.7M140.6M
Liabilities And Stockholders Equity763.8M786.9M888.7M1.0B1.2B763.9M
Non Current Liabilities Total81.9M39.6M36.4M35.4M31.9M30.3M
Inventory30.0M47.1M53.8M44.2M39.8M34.4M
Other Current Assets35.1M9.1M(1K)187.9M216.1M226.9M
Other Stockholder Equity99.7M168.2M168.2M106.7M122.7M92.7M
Total Liab241.7M188.1M176.3M159.8M143.8M203.6M
Total Current Assets411.9M435.6M494.4M596.2M685.7M720.0M
Short Term Debt39.3M90K623K(51K)(45.9K)(43.6K)
Current Deferred Revenue46.5M90K623K51K45.9K43.6K
Other Liab37.5M40.4M38.0M39.5M45.5M41.5M
Net Tangible Assets290.3M406.1M522.1M598.8M688.6M433.3M
Net Invested Capital598.5M598.8M712.4M856.3M984.8M631.7M
Net Working Capital252.1M287.1M354.5M471.8M542.6M569.8M
Property Plant Equipment363.4M351.4M344.3M343.5M309.2M286.9M
Property Plant And Equipment Gross569.8M602.7M678.2M413.3M372.0M455.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Par Stock

Balance Sheet is a snapshot of the financial position of Par Drugs And at a specified time, usually calculated after every quarter, six months, or one year. Par Drugs Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Par Drugs and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Par currently owns. An asset can also be divided into two categories, current and non-current.